Sowell Financial Services LLC Acquires 40,735 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Sowell Financial Services LLC bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the third quarter, HoldingsChannel.com reports. The fund bought 40,735 shares of the company’s stock, valued at approximately $3,039,000.

A number of other institutional investors have also recently modified their holdings of KNSA. Sterling Capital Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 911.4% during the 3rd quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock valued at $112,000 after purchasing an additional 1,358 shares during the last quarter. Curry Webb Wealth Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $29,000. Robeco Institutional Asset Management B.V. purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $1,046,000. USA Financial Formulas purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $69,000. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 3.9% during the third quarter. TD Waterhouse Canada Inc. now owns 17,343 shares of the company’s stock valued at $1,304,000 after purchasing an additional 652 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Michael Megna sold 4,600 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

KNSA has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research note on Wednesday. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Canaccord Genuity Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Stock Down 5.5%

Shares of KNSA opened at $92.24 on Friday. The business has a 50-day simple moving average of $79.15 and a two-hundred day simple moving average of $60.03. The stock has a market cap of $7.20 billion, a price-to-earnings ratio of 70.95 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 52 week low of $36.56 and a 52 week high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.